The impact of lymph node metastatic rate on clinical outcome following 131I therapy in patients with papillary thyroid carcinoma
GAO Wen1,2, LIANG Jun1, ZHAO Teng1, LI Jiao1, LIN Yansong2
1.Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China; 2.Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
GAO Wen, LIANG Jun, ZHAO Teng, et al. The impact of lymph node metastatic rate on clinical outcome following 131I therapy in patients with papillary thyroid carcinoma[J]. China Oncology, 2016, 26(1): 67-72.
HU Xichun, HU Zhihuang, WANG Biyun, WANG Jialei, TAO Rong, ZHANG Jian, GUO Weijian, CHEN Jie, LUO Zhiguo, LI Ting, HUANG Mingzhu, QIU Lixin, SANG Youzhou.
COVID-19 and systemic anti-cancer therapy
[J]. China Oncology, 2022, 32(6): 499-511.